- Other Post Graduate Training - UT Southwestern Medical Center (1989-1994)
- Fellowship - Harvard Medical School/Brigham & Women's Hospital (1999-2000), Gynecologic Pathology
- Residency - Harvard Medical School/Brigham & Women's Hospital (1997-1999), Anatomic Pathology
- Medical School - UT Southwestern Medical Center (1987-1996)
- Graduate School - UT Southwestern Medical Center (1989-1994), Genetics & Development
Diego Castrillon, M.D., Ph.D.
- Vernie A. Stembridge, M.D., Distinguished Chair in Pathology
- Pathology
- Cervical Cancer
- Endometrial Cancer and Precancer
Biography
Diego H. Castrillón, M.D., Ph.D., holds the Vernie A. Stembridge, M.D., Distinguished Chair in the Department of Pathology and is a Professor in the Department of Obstetrics and Gynecology at UT Southwestern Medical Center. He specializes in gynecologic pathology.
Dr. Castrillón earned his doctoral degree in genetics and development and his medical degree as part of the Medical Scientist Training Program at UT Southwestern. He completed a residency in anatomic pathology and a clinical fellowship in gynecologic and obstetric pathology at Brigham and Women’s Hospital at Harvard Medical School in Boston, Massachusetts. He also completed a postdoctoral research fellowship in cancer genetics at the Dana Farber Cancer Institute at Harvard Medical School. He earned his bachelor’s degree at the Massachusetts Institute of Technology in Cambridge, Massachusetts.
Board certified in anatomic pathology, he joined the UT Southwestern faculty in 2003. Dr. Castrillón serves as Director of Investigative Pathology for the Department of Pathology and is a member of the UT Southwestern Harold C. Simmons Comprehensive Cancer Center and the Cecil H. and Ida Green Center for Reproductive Biology Sciences.
He is an elected Fellow of the American Society for Clinical Investigation and the American Association for the Advancement of Science Section on Medical Sciences. He is also a member of the American Association for Cancer Research, the United States and Canadian Academy of Pathology, the European Society of Gynaecological Oncology, the International Society of Gynecological Pathologists, the European Society for Medical Oncology, and the European Society of Pathology.
His clinical interests include pathologic diagnosis of obstetric and gynecologic disease with a focus on endometrial (uterine) cancer and precancer. He also directs the Castrillón research laboratory, which is devoted to the study of endometrial cancer. He has developed a number of new approaches and model systems to diagnose and study this common yet understudied malignancy.
Dr. Castrillón has delivered many presentations, contributed to the books New-opathies: An Emerging Molecular Reclassification of Human Disease and Gynecologic and Obstetric Pathology, and published more than 100 academic articles related to his areas of expertise. He is a consulting editor for the Journal of Clinical Investigation and the International Journal of Gynecologic Pathology and an ad hoc reviewer for numerous other scholarly journals. He also holds five patents.
Personal Note
When he’s not working, Dr. Castrillón enjoys traveling and spending time with his family.
Education & Training
Professional Associations & Affiliations
- American Association for Cancer Research
- American Association for the Advancement of Science
- American Society for Clinical Investigation
- European Society for Medical Oncology
- European Society of Gynaecological Oncology
- European Society of Pathology
- International Society of Gynecological Pathologists
- United States and Canadian Academy of Pathology
Honors & Awards
- Elected Fellow 2022, American Association for the Advancement of Science, Section on Medical Sciences
- 6th Annual Lippard Endowed Lecture 2021, Co-hosted by MIT Koch and Massachusetts General Hospital Cancer Center
- Individual Investigator Research Award, 2010, 2019, Cancer Prevention Research Institute of Texas
- Membership 2017, International Society of Gynecologic Pathologists
- Vernie A. Stembridge, M.D., Distinguished Chair in Pathology, 2014-present, UT Southwestern
- John H. Childers, M.D. Professorship of Pathology 2012-2014, UT Southwestern
- Outstanding Teacher Award 2011, UT Southwestern Medical School Class of 2013
- Jean D. Wilson Distinguished Alumnus Lecture 2010, UT Southwestern Medical Scientist Training Program
- Research Scholar Award 2009, American Cancer Society
- Elected Member 2009, American Society for Clinical Investigation
- Mouse Pathobiologist Award 2007, National Institutes of Health
- Kimmel Scholar Award in Translational Science 2004, Sidney Kimmel Foundation for Cancer Research
- Damon Runyon Postdoctoral Fellowship 2000, Damon Runyon Cancer Research Foundation
- Stanley L. Robbins Research Award 1999, Brigham and Women’s Hospital at Harvard Medical School
Books & Publications
-
Books
-
New-opathies: An Emerging Molecular Reclassification of Human Disease
Friedberg, E.C., Castrillón, D.H., Galindo, R.L., Wharton, K.A. (2012), World Scientific Press -
Development and Maldevelopment of the Female Reproductive Tract in Gynecologic and Obstetric Pathology, Volume 1
Castrillón, D.H. (2019), Springer
-
New-opathies: An Emerging Molecular Reclassification of Human Disease
-
Publications
-
FOXA2 suppresses endometrial carcinogenesis and epithelial-mesenchymal transition by regulating enhancer activity.
Sahoo SS, Ramanand SG, Gao Y, Abbas A, Kumar A, Cuevas IC, Li HD, Aguilar M, Xing C, Mani RS, Castrillon DH, The Journal of clinical investigation 2022 Jun 132 12 -
Histopathologic diagnosis of endometrial precancers: Updates and future directions.
Chen H, Strickland AL, Castrillon DH, Seminars in diagnostic pathology 2021 Dec -
Reliable Identification of Endometrial Precancers Through Combined Pax2, ?-Catenin, and Pten Immunohistochemistry.
Aguilar M, Chen H, Rivera-Colon G, Niu S, Carrick K, Gwin K, Cuevas IC, Sahoo SS, Li HD, Zhang S, Zheng W, Lucas E, Castrillon DH, The American journal of surgical pathology 2021 Sep -
Serial genomic analysis of endometrium supports the existence of histologically indistinct endometrial cancer precursors.
Aguilar M, Zhang H, Zhang M, Cantarell B, Sahoo SS, Li HD, Cuevas IC, Lea J, Miller DS, Chen H, Zheng W, Gagan J, Lucas E, Castrillon DH, The Journal of pathology 2021 Jan -
A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response.
Li HD, Lu C, Zhang H, Hu Q, Zhang J, Cuevas IC, Sahoo SS, Aguilar M, Maurais EG, Zhang S, Wang X, Akbay EA, Li GM, Li B, Koduru P, Ly P, Fu YX, Castrillon DH, JCI insight 2020 Jul 5 14 -
Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition.
Cuevas IC, Sahoo SS, Kumar A, Zhang H, Westcott J, Aguilar M, Cortez JD, Sullivan SA, Xing C, Hayes DN, Brekken RA, Bae-Jump VL, Castrillon DH, Proceedings of the National Academy of Sciences of the United States of America 2019 Nov -
PI3K Pathway Effectors pAKT and FOXO1 as Novel Markers of Endometrioid Intraepithelial Neoplasia.
Strickland AL, Rivera G, Lucas E, John G, Cuevas I, Castrillon DH International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2018 Sep -
Polymerase-mediated ultramutagenesis in mice produces diverse cancers with high mutational load.
Li HD, Cuevas I, Zhang M, Lu C, Alam MM, Fu YX, You MJ, Akbay EA, Zhang H, Castrillon DH The Journal of clinical investigation 2018 Aug 128 9 4179-4191 -
Control of Oocyte Reawakening by Kit.
Saatcioglu HD, Cuevas I, Castrillon DH PLoS genetics 2016 Aug 12 8 e1006215 -
LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment.
Peña CG, Nakada Y, Saatcioglu HD, Aloisio GM, Cuevas I, Zhang S, Miller DS, Lea JS, Wong KK, DeBerardinis RJ, Amelio AL, Brekken RA, Castrillon DH The Journal of clinical investigation 2015 Sep -
Cooperation between p53 and the telomere-protecting shelterin component Pot1a in endometrial carcinogenesis.
Akbay EA, Peña CG, Ruder D, Michel JA, Nakada Y, Pathak S, Multani AS, Chang S, Castrillon DH Oncogene 2012 Jun -
Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy.
Contreras CM, Akbay EA, Gallardo TD, Haynie JM, Sharma S, Tagao O, Bardeesy N, Takahashi M, Settleman J, Wong KK, Castrillon DH Disease models & mechanisms 2010 Mar-Apr 3 3-4 181-93 -
Somatic LKB1 mutations promote cervical cancer progression.
Wingo SN, Gallardo TD, Akbay EA, Liang MC, Contreras CM, Boren T, Shimamura T, Miller DS, Sharpless NE, Bardeesy N, Kwiatkowski DJ, Schorge JO, Wong KK, Castrillon DH PloS one 2009 4 4 e5137 -
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis.
Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, Miao L, Tothova Z, Horner JW, Carrasco DR, Jiang S, Gilliland DG, Chin L, Wong WH, Castrillon DH, DePinho RA Cell 2007 Jan 128 2 309-23
-
FOXA2 suppresses endometrial carcinogenesis and epithelial-mesenchymal transition by regulating enhancer activity.
Research
- Gynecologic Pathology
- Gynecologic Cancers
- Endometrial Cancers
Clinical Focus
- Cervical Cancer
- Endometrial Cancer and Precancer
- Gestational Trophoblastic Disease
- Ovarian Cancer
- Pathologic Diagnosis of Obstetric and Gynecologic Disease